Points clés
- 1Biosimilar adalimumab preserved remission at roughly 9% of the branded cost; switching followed a structured rheumatology protocol.
- 2Interval extension of a biologic is a clinical decision — doing it unsupervised risks losing hard-won remission.
- 3The product and batch were recorded at every dose, because biologic pharmacovigilance is product-specific.
- 4Once the biologic was affordable, the patient also stopped skipping monitoring bloods — an unplanned safety gain.
Aperçu du cas
- Profil du patient
- Composite profile — 52-year-old, seropositive rheumatoid arthritis in remission
- Pays
- United Kingdom, private supplementary treatment
- Affection
- Rheumatoid arthritis
- Médicament
- Adalimumab plus methotrexate and folic acid
Coût occidental
~$62,000 per year
Alternative de référence
~$5,300 per year reference
Impact
~$56,700 per year
Sur cette page
1Stable disease, unstable finances
After several years of escalating therapy, this patient reached sustained remission on a TNF inhibitor combined with low-dose weekly methotrexate. Remission in RA is valuable and fragile; the priority was not to disturb it.
A change in her supplementary coverage moved a substantial share of the biologic cost to her directly. She considered extending her injection interval to make each pen last longer.
2The biosimilar switch
Adalimumab biosimilars have been widely adopted across European rheumatology services since the reference product lost exclusivity. Her rheumatology team had a structured switching pathway already in place.
Biosimilars are approved only after a comparability programme demonstrates no clinically meaningful differences from the reference product in quality, safety and efficacy.
| Component | Before | After | Reduction |
|---|---|---|---|
| Adalimumab 40 mg, every 2 weeks | ~$59,600 | ~$4,900 | 92% |
| Methotrexate 15 mg weekly | ~$1,900 | ~$290 | 85% |
| Folic acid | ~$180 | ~$22 | 88% |
| Monitoring bloods | ~$320 | ~$88 | 73% |
| Annual total | ~$62,000 | ~$5,300 | 91% |
3The switching protocol
Rheumatology biosimilar switching is well-established and follows a consistent pattern worth knowing about.
- 1Baseline disease activity score recorded before the switch.
- 2Patient education on the new injection device, which differed from the original.
- 3Switch made at a scheduled dose with no gap in therapy.
- 4Disease activity reassessed at 12 weeks.
- 5Injection-site reactions and any new symptoms reported actively.
- 6Product name and batch number recorded at every administration.
4Outcome
Disease activity at 12 weeks was unchanged and remission was maintained at the twelve-month review. She reported the new device as slightly less comfortable but manageable after training.
Because the biologic was now affordable, she also stopped skipping the monitoring blood tests she had been deferring to save money — an unplanned safety improvement.
5About this case study
This is a composite case study. It illustrates a real, documented price pattern using a representative patient profile rather than a specific identifiable individual. Figures are reference ranges, not quotations, and outcomes vary by person, dose and market.
Statistics alone cannot carry the weight of a decision about medicine. A line like 'the same course is 340 times cheaper' means nothing until you can see what it did to one household's bills, monitoring schedule and peace of mind.
The only reason we show any switch is to illustrate a pattern. Your own move must be planned with your prescriber.
Jivan publishes pricing and educational information only. Do not start, stop, substitute or re-dose any medicine without a licensed physician's approval.
Ce que montre le jeu de données Jivan
- 56.4×
- écart moyen de prix Immunology
- 64%
- des ancres dépassent 10×
- 344×
- plus grand écart documenté
Across our Immunology anchors, 25 referenced molecules average a 56.4× price gap, 64% of them are at least 10× cheaper in India, and the widest documented comparison is Colchicine at 344×. Immunology anchors show biologic prices behaving differently from small molecules: savings are large but less extreme, consistent with the higher cost of living-cell production.
Calculé en direct à partir de 25 anchors
Questions fréquentes
Structured switching programmes in rheumatology have been widely implemented, with disease activity monitored before and after. Discuss the evidence and the monitoring plan with your rheumatology team.
Only under rheumatology supervision. Some services taper frequency in sustained remission as a monitored protocol with defined flare criteria. Doing it unsupervised risks losing remission.
Biologic pharmacovigilance is product-specific. If an adverse event occurs, the exact product and batch must be identifiable, which is why biologics are not treated like interchangeable small-molecule generics.
Sources et lectures complémentaires
Chaque fait ci-dessus est traçable vers une source primaire publique. Nous citons les régulateurs et les organismes de santé publique, pas les vendeurs commerciaux.
- 1Biosimilar Medicines OverviewEuropean Medicines Agency
- 2Medicines and Healthcare products Regulatory AgencyUK Government
- 3MedlinePlus Drug InformationU.S. National Library of Medicine
- 4Generic Drug FactsU.S. Food & Drug Administration
Comment cet article a été rédigé
Rédigé et recherché
Pricing Research Editor, Jivan Editorial TeamRelu éditorialement
Editorial Review Board — Jivan
Composite profile assembled from documented price patterns; not a named individual.
Avertissement médical important
Consultez toujours un médecin avant de changer de médicament, de dose ou de marque. Jivan fournit des informations éducatives et tarifaires et ne remplace ni un diagnostic ni les soins d'urgence.